Made in India Heart Stent Steals the Spotlight: Outperforms US Market Leader in Global Trial
Published: Oct 31, 2025
Updated: Nov 04, 2025
Published: Oct 31, 2025
Updated: Nov 04, 2025
India's medical innovation has taken a giant leap forward. A homegrown heart stent, Supraflex Cruz, has outperformed a leading US-made stent in a landmark clinical trial - earning international recognition and showcasing the country's growing excellence in advanced healthcare technology.
In the TUXEDO-2 trial, conducted across 66 top cardiology centres in India, researchers compared the Made-in-India Supraflex Cruz with the internationally renowned Xience stent from the USA. The results were extraordinary. The Indian stent not only proved to be as effective as its global competitor- it demonstrated a lower failure rate in high-risk patients, including those with diabetes and complex multi-vessel heart disease. Notably, 80% of participants in the trial had triple vessel disease, one of the most challenging heart conditions to treat.
The groundbreaking findings were presented at an international cardiology conference by Dr Upendra Kaul, Chairman and Dean of Batra Hospital, New Delhi, one of India's leading cardiologists.
Dr Kaul shared that the Indian-made stent not only matched the performance of the US-made Xience but also recorded significantly fewer serious complications, including cardiac death, heart attacks, and repeat procedures.
Manufactured in Surat, Supraflex Cruz represents the power of Indian innovation, combining quality, safety, and affordability. It stands as proof that India is capable of producing world-class medical devices that meet global standards while being accessible to patients everywhere.
The TUXEDO-2 trial was led by Dr Kaul, along with Dr Sripal Bangalore and Dr Priyadarshini Arambam, ensuring scientific accuracy and clinical integrity throughout the study.
The success of Supraflex Cruz is not just a medical breakthrough; it's a symbol of hope and progress. It shows how Indian ingenuity is shaping the future of global healthcare, creating solutions that are effective, reliable, and life-saving.
If you or someone you care about needs advanced cardiac care, you can now connect directly with Dr Upendra Kaul through MediGence.
MediGence connects patients worldwide with India's top cardiologists and accredited hospitals. From expert consultations and treatment planning to travel coordination and follow-up care, MediGence ensures a seamless, transparent, and patient-focused healthcare experience.
Your heart deserves the best care.
Connect with Dr Upendra Kaul through MediGence and take the next step toward a healthier, stronger future.
Alvina Hasan is a dedicated medical researcher and scientific writer with a strong foundation in the pharmaceutical sciences. She holds a B.Pharm from Jamia Hamdard University and an M.Pharm in Quality Assurance from DIPSAR University. With deep medical expertise and a strong interest in healthcare communication, she focuses on transforming complex clinical and scientific information into clear, engaging, and easy-to-understand narratives. She develops insightful healthcare articles and research-driven pieces designed to support both medical professionals and patients, helping bridge the gap between advanced medical knowledge and practical understanding.
Amit Bansal is a serial entrepreneur, Co-Founder, and CEO of MediGence. He has more than 17 years of strong technology experience. Having worked for some of the recognized companies in India, Australia and traveled worldwide to help businesses to grow multi-folded under his leadership and strategic guidance.
Delhi, India
Istanbul, Turkey
Istanbul, Turkey
Istanbul, Turkey
Active
.png)
.png)
.jpg)
